Table III.

Plasma and tumor levels of CXCL9 and CXCL10 in response to systemic IL-2 and/or intratumor CXCL9 therapya

TreatmentPlasma CXCL10 (ng/ml)Plasma CXCL9 (ng/ml)Sum of Plasma CXCR3 Ligands (ng/ml)Tumor CXCL10 (ng/ml)Tumor CXCL9 (ng/ml)Sum of Tumor CXCR3 Ligands (ng/ml)Chemotactic Gradient (Tumor-plasma, ng/ml)
Control0.15 ± 0.050.000.150.10 ± 0.0140.6 ± 0.50.70+0.55
IL-21.40 ± 0.571.50 ± 0.32.900.11 ± 0.0062.0 ± 0.082.11−0.79
CXCL90.10 ± 0.10.90 ± 0.071.000.13 ± 0.0096.9 ± 2.77.03+6.03
IL-2 + CXCL91.00 ± 0.11.08 ± 0.152.080.084 ± 0.0234.7 ± 1.34.78+2.70
  • a Gradient of higher concentration in tumor compared to plasma.